Why are 2 doses of Shingrix necessary?

Two Shingrix doses are needed because a single shot does not reliably produce the immune response needed to protect older adults against shingles.

The vaccine uses a recombinant protein (gE) plus a strong adjuvant (AS01B) that drives both antibodies and CD4+ T cells [2]. One dose generates some immunity, but a second dose given two months later is what pushes most people into a high-responder range. A month after the second dose, about 98% of recipients had detectable antibodies, with titers about 39-fold higher than placebo [2]. A Medicare real-world study found that a single dose had only 56.9% effectiveness against shingles, while two doses raised that to 70.1% [3]. Induces a 25-fold rise in CD4+ T cells [2]; one dose alone does not produce that.

The two-dose schedule was tested in the manufacturer-funded ZOE-50 and ZOE-70 trials, which reported 97.2% efficacy in the 50+ group and 89.8% in the 70+ group [3]. Those trials gave two doses and followed people for an average of about three to four years [3]. No head-to-head trial of one dose versus two exists in a truly unvaccinated control group. The durability data builds in: protection after two doses holds at 84.1% efficacy through year eight [3]. The cost-effectiveness models that drive policy assume two doses because a single shot leaves a gap big enough to lower the numbers substantially [1].

The short answer: the schedule exists because one shot does not reliably trigger enough cellular immunity, and the two-shot regimen is what the pivotal trials tested. The evidence for two doses over one is real but built entirely on manufacturer-funded trials and observational data, not a randomized comparison between the two schedules.

My call: two doses are necessary for the protection the trials claim, but the absence of a one-dose versus two-dose RCT means the true gap is less certain than the bold numbers suggest. Confidence: moderate.